Shire launches ADHD med Mydayis as it weighs a neuroscience exit by Eric Sagonowsky Monday, August 28, 2017 Shire has rolled out Mydayis, its new Adderall formulation, at a list price of $271 per month. The aim? Hitting $500 million in sales.
Shire looks for more ADHD mileage with new data on long-acting prospect by Carly Helfand Tuesday, July 5, 2016 Shire’s long-delayed ADHD candidate has racked up more positive data in its quest to finally make it to market. But will it find space to compete?
With weight-control peers flailing, Shire keeps growing Vyvanse by Carly Helfand Wednesday, May 11, 2016 A trio of companies has struggled mightily at growing the obesity market. Yet Shire’s Vyvanse hasn’t had a problem in its weight-control segment.
FDA fast-tracks Shire's Vyvanse for binge eating; Merck starts shipping Keytruda; by Tracy Staton Monday, September 15, 2014 @FiercePharma: Tops in FP this weekend: Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets. Article | Follow @FiercePharma @EricPFierce: Apotex, which has...
